Investors
.jpeg)
StabiLux’s innovation uses nano-technology to completely change imaging resolution.
Go to Market Strategy:
StabiLux® primarily plans to manufacture and sell dyes to leading reagent producers such as BD, Bio-Legends, Beckman Coulter, and MilliporeSigma. Since our technology can be adapted to any reagent, we offer them an opportunity to enhance/improve their entire product catalog.
Financial Projection:
The company is seeking outside investment as well as strategic partnerships. We are currently raising $3.0M Series A. Funds will be used for product launch and expansion, scale, and additional IP filing. The company has raised 2.7M to date with $1.7M in grants and other non-dilutive funding. Additional grant funding has also been received or pending.
Intellectual Property:
A foundational patent was filed and a broad range of patent protection has been submitted. Broad PCT coverage and broad-based US filing.